University of Zurich
uzh.chTotal trials
1,033
Active
130
Phase 3
42
Total enrollment
623,325
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ACETAZOLAMIDE oral | — | — | — | 26 | |||
| Paracetamol | — | — | — | — | — | 2 | |
| Bryophyllum | — | — | — | — | 2 | ||
| Tramadol | — | — | — | — | — | 1 | |
| Diclofenac | — | — | — | — | — | 1 | |
| Oxygen | — | — | — | — | 5 | ||
| Temozolomide | — | — | — | — | — | 2 | |
| Tideglusib | — | — | — | — | — | 1 | |
| Propranolol | — | — | — | — | — | 1 | |
| Ruxolitinib Topical Cream | — | — | — | — | — | 1 | |
| Control Group | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 1 | |
| Sulfasalazine | — | — | — | — | — | 1 | |
| Memantine | — | — | — | — | — | 1 | |
| Vortioxetine | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| ALUTARD SQ® Felis domesticus | — | — | — | — | — | 1 | |
| 50% N2O plus 50% O2 | — | — | — | — | — | 1 | |
| Sevoflurane | — | — | 9 | ||||
| Nivaquine ® | — | — | — | — | — | 1 | |
| intrathecal nivolumab and intrathecal ipilimumab | — | — | — | — | — | 1 | |
| Intranasal ketamine hydrochloride | — | — | — | — | — | 1 | |
| VOCABRIA 30Mg | — | — | — | — | — | 1 | |
| EDURANT 25Mg | — | — | — | — | — | 1 | |
| Cabotegravir Injectable Suspension | — | — | — | — | — | 1 | |
| Rilpivirine Injectable Suspension | — | — | — | — | — | 1 | |
| Intact proviral DNA assay | — | — | — | — | — | 1 | |
| Full-length sequencing | — | — | — | — | — | 1 | |
| Fecal Microbiota Transplantation | — | — | — | — | — | 1 |
Next readouts
- 2024-10-04
- 2025-07-31
- 2025-12
- 2025-12
- 2025-12-01
- 2025-12-31
- 2025-12-31
- 2025-12-31
- 2026-04-22
- 2026-04-30
Top conditions
- Healthy31
- Pulmonary Hypertension24
- Stroke17
- Chronic Obstructive Pulmonary Disease16
- High Altitude Pulmonary Hypertension16
- Glaucoma14
- Spinal Cord Injury11
- Coronary Artery Disease10
Frequently asked questions about University of Zurich
- How many clinical trials does University of Zurich have on ClinicalTrials.gov?
- University of Zurich is listed as the lead sponsor on 1,033 clinical trials in ClinicalTrials.gov, 130 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Zurich's trials are in Phase 3?
- 42 of University of Zurich's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does University of Zurich focus on?
- University of Zurich's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Hypertension, Stroke, Chronic Obstructive Pulmonary Disease, High Altitude Pulmonary Hypertension.
- When are University of Zurich's next clinical trial readouts?
- University of Zurich has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy”, expected around 2024-10-04.